Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy | Zendy

Elke Hattingen | Zendy; Oliver Bähr | Zendy; Johannes Rieger | Zendy; Stella Blasel | Zendy; Jörg Steinbach | Zendy; Ulrich Pilatus | Zendy

Open Access

Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy

Author(s) -

Elke Hattingen,

Oliver Bähr,

Johannes Rieger,

Stella Blasel,

Jörg Steinbach,

Ulrich Pilatus

Publication year - 2013

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0056439

Subject(s) - phosphocholine , metabolite , in vivo , choline , chemistry , phospholipid , glioblastoma , medicine , cancer research , biochemistry , biology , phosphatidylcholine , membrane , microbiology and biotechnology

Purpose Metabolic changes upon antiangiogenic therapy of recurrent glioblastomas (rGBMs) may provide new biomarkers for treatment efficacy. Since in vitro models showed that phospholipid membrane metabolism provides specific information on tumor growth we employed in-vivo MR-spectroscopic imaging (MRSI) of human rGBMs before and under bevacizumab (BVZ) to measure concentrations of phosphocholine (PCho), phosphoethanolamine (PEth), glycerophosphocholine (GPC), and glyceroethanolamine (GPE). Methods 1 H and 31 P MRSI was prospectively performed in 32 patients with rGBMs before and under BVZ therapy at 8 weeks intervals until tumor progression. Patients were dichotomized into subjects with long overall survival (OS) (>median OS) and short OS (

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research